

5 September 2022

ASX Code: MXC

LSE Code: MXC

## Dispatch of General Meeting Documents

A  
S  
X  
  
R  
E  
L  
E  
A  
S  
E

**MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company')** would like to advise that it has commenced distribution of the accompanying letter to shareholders, advising them of details of the General Meeting of shareholders to be held on Wednesday, 5 October 2022 at 4:00pm (AWST) at 1202 Hay Street, West Perth, Western Australia 6005.

Also being dispatched to shareholders today is the Notice of General Meeting for the above meeting.

--Ends--

**Authorised for release by the Company Secretary, for further information please contact:**

**MGC Pharmaceuticals Ltd**

Roby Zomer  
CEO & Managing Director  
+61 8 6382 3390  
[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

**UK Broker – Turner Pope**

Andy Thacker  
+44 203 657 0050  
[info@turnerpope.com](mailto:info@turnerpope.com)

**MGC Pharmaceuticals Ltd**

David Lim  
Company Secretary  
+61 8 6382 3390  
[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

**UK PR Advisors – Tavistock**

Charles Vivian / Tim Pearson  
+44 207 920 3150  
[mgcpharma@tavistock.co.uk](mailto:mgcpharma@tavistock.co.uk)

### About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels



5 September 2022

**LETTER TO SHAREHOLDERS – UPCOMING GENERAL MEETING**

Dear Shareholder,

**MGC Pharmaceuticals Ltd (Company or MGC Pharma)** advises that it is convening a General Meeting of shareholders at 4:00pm (AWST) on Wednesday the 5<sup>th</sup> of October 2022 at 1202 Hay Street, West Perth, Australia 6005.

The Company is continuing to monitor the impact of the COVID-19 virus in Western Australia, and follow guidance from the Federal and State Governments. Having considered the current circumstances, the directors have made the decision that a physical meeting will be held. Accordingly, Shareholders will be able to attend the Meeting in person, subject to them complying with any Government orders relating to COVID-19 in place at the time that the meeting is held.

In accordance with the Corporations Act 2001 (*Cth*) the Company will not be sending hard copies of the Notice of Meeting to shareholders unless a shareholder has requested a hard copy.

A copy of the Company's Notice of Meeting released to the ASX on 5 September 2022 is available to view on the Company's Website at <https://mgcpharma.com.au/asx-investor-centre/announcements/>.

The directors strongly encourage all shareholders to lodge a directed proxy form prior to the meeting. If you have provided an email address and have elected to receive electronic communications from the Company, you will also be sent an email with a link to an electronic copy of the important meeting documents.

If you have not elected to receive notices by email, a copy of your personalised proxy form is enclosed for your convenience. Proxy votes can be lodged with the Company's Share Registry, Computershare Investor Services Pty Ltd online by using the following options:

- |                  |  |
|------------------|--|
| Online           | At <a href="http://www.investorvote.com.au">www.investorvote.com.au</a>  |
| By mail          | Share Registry – Computershare Investor Services Pty Limited, GPO Box 242, Melbourne Victoria 3001, Australia  |
| By fax           | 1800 783 447 (within Australia)<br>+61 3 9473 2555 (outside Australia)   |
| By mobile        | Scan the QR code on your proxy form and follow the prompts   |
| Custodian Voting | For Intermediary Online subscribers only (custodians) please visit <a href="http://www.intermediaryonline.com">www.intermediaryonline.com</a> to submit your voting intentions |

Your sincerely

**On behalf of MGC Pharmaceuticals Ltd,**

**David Lim**  
Company Secretary